Earnings Feed
Start Free
Mobia Medical, Inc.·4

May 11, 9:58 PM ET

Tansey Casey M 4

4 · Mobia Medical, Inc. · Filed May 11, 2026

Research Summary

AI-generated summary of this filing

Updated

Mobia Medical (MOBI) Director Casey M. Tansey Buys 66,666 Shares

What Happened
Casey M. Tansey, a director (reported as the managing partner of related investment vehicles), reported an open‑market purchase and multiple conversions of derivative securities into common stock. The clearest cash purchase was 66,666 shares at $15.00 per share on 2026-05-11 for $999,990. The filing also shows multiple derivative grants and conversions reported earlier and on 2026-05-11, including grants on 2026-02-06 (3,769,090.08 derivative shares) and 2026-02-10 (2,000,000 derivative shares) and several conversion line items on 2026-05-11 (e.g., 166,666; 314,090; 3,312,736 and additional conversion/disposition entries totaling several million shares). Footnotes tie many conversions to automatic conversions at the company’s IPO.

Key Details

  • Transaction dates & prices: Open‑market purchase 66,666 shares on 2026-05-11 at $15.00 ($999,990). Multiple derivative grants reported 2026-02-06 and 2026-02-10; several conversions reported on 2026-05-11 (see Form 4 for full line‑by‑line counts).
  • Shares reported after transactions: the filing discloses shares held by related USVP funds totaling 3,626,826 shares (1,623,245 + 1,906,809 + 96,772) per footnote; the reporting person disclaims direct beneficial ownership except for any pecuniary interest.
  • Notable footnotes: F1 explains convertible notes automatically converted at the IPO (conversion price = lower of 80% of offering price or a valuation-based formula). F5 notes certain preferred shares converted to common immediately before the offering. F6 notes some transactions occurred prior to registration and are reported under Rule 16a-2(a). F7 notes a stock option grant vests over three years. F3–F4 describe the reporting person’s role (managing partner) and voting/dispositive power for the funds.
  • Filing timeliness: The report was filed 2026-05-11 while the Period of Report includes transactions back to 2026-02-06, indicating the Form 4 covers earlier grants and appears to have been filed after some of those grant dates.

Context

  • The large, multi‑million share line items are primarily conversions of pre‑IPO instruments (convertible notes and preferred stock) into common stock per the IPO terms — these are corporate capital‑structure changes more than routine buy/sell signals.
  • The $999,990 open‑market purchase is the clearest outright personal buy (a straightforward cash purchase, often viewed by investors as a more direct bullish signal than restructurings).
  • The reporting person is the managing partner of the investment vehicles listed; the filing attributes shares to those funds and includes a standard disclaimer of personal beneficial ownership except for pecuniary interest.

For exact line‑by‑line counts and the company’s specified conversion mechanics, see the Form 4 and its footnotes (Accession 0001628280-26-033820).

Insider Transaction Report

Form 4
Period: 2026-02-06
Mobia Medical, Inc.MOBI
Tansey Casey M
Director
Transactions
  • Conversion

    Common Stock

    [F1]
    2026-05-11+166,666→ 166,666 total
  • Purchase

    Common Stock

    2026-05-11$15.00/sh+66,666$999,990→ 233,332 total
  • Conversion

    Common Stock

    [F1][F2][F3][F4]
    2026-05-11+314,090→ 314,090 total(indirect: See Footnote)
  • Conversion

    Common Stock

    [F5][F2][F3][F4]
    2026-05-11+3,312,736→ 3,626,826 total(indirect: See Footnote)
  • Award

    Convertible Notes

    [F1][F6]
    2026-02-06$3769090.08/sh+3,769,090.08$14,206,040,031,154→ 3,769,090.08 total(indirect: By U.S. Venture Partners Select Fund I, L.P)
    → Common Stock (314,090 underlying)
  • Award

    Convertible Notes

    [F1][F6]
    2026-02-10$2000000.00/sh+2,000,000$4,000,000,000,000→ 2,000,000 total
    → Common Stock (166,666 underlying)
  • Award

    Stock Option

    [F7]
    2026-05-07+31,520→ 31,520 total
    Exercise: $15.00Exp: 2026-05-07→ Common Stock (31,520 underlying)
  • Conversion

    Convertible Notes

    [F1]
    2026-05-11−3,769,090.08→ 0 total(indirect: By U.S. Venture Partners Select Fund I, L.P)
    → Common Stock (314,090 underlying)
  • Conversion

    Convertible Notes

    [F1]
    2026-05-11−2,000,000→ 0 total
    → Common Stock (166,666 underlying)
  • Conversion

    Series F Preferred Stock

    [F5][F2][F3][F4]
    2026-05-11−5,642,738→ 0 total(indirect: See Footnote)
    → Common Stock (1,620,078 underlying)
  • Conversion

    Series E-2 Preferred Stock

    [F5][F2][F3][F4]
    2026-05-11−5,895,530→ 0 total(indirect: See Footnote)
    → Common Stock (1,692,658 underlying)
Footnotes (7)
  • [F1]The Convertible Notes automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "Offering"). The conversion price is the lower of (a) 80% of the Offering price per share and (b) the valuation of the Issuer immediately prior to the closing of the Offering divided by the number of fully diluted shares of capital stock (on an as-converted basis) outstanding immediately prior to Offering, excluding the Convertible Notes.
  • [F2]After the transactions reported herein, includes (i) 1,623,245 shares of Common Stock held by U.S. Venture Partners Select Fund I, L.P. ("USVP SFI") on its own behalf and as a nominee for U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A" and, together with USVP SFI, the "USVP Select Funds"), (ii) 1,906,809 shares of Common Stock held by U.S. Venture Partners XII, L.P. ("USVP XII"), and (iii) 96,772 shares of Common Stock held by U.S. Venture Partners XII-A, L.P. ("USVP XII-A" and, together with USVP XII, the "USVP XII Funds").
  • [F3]Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of USVP XII and USVP XII-A and may be deemed to have sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of USVP SFI and USVP SFI-A and may be deemed to have sole voting and dispositive power with respect to the securites held by USVP SFI and USVP SFI-A.
  • [F4]The Reporting Person is the managing partner and a managing member of each of PMG XII and PMG Select, and may be deemed to share voting and dispositive power with respect to the securites described herein. The Reporting Person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.
  • [F5]Each share of the Series F Preferred Stock and Series E-2 Preferred Stock converted into Common Stock immediately prior to the completion of the Offering pursuant to its terms.
  • [F6]This transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended, in connection with the Offering, and is reported herein pursuant to Rule 16a-2(a).
  • [F7]The stock option will vest in three substantially equal installments on the first three anniversaries of the grant date.
Signature
/s/ Chase Leavitt, Attorney-in-Fact|2026-05-11

Documents

1 file
  • 4
    wk-form4_1778551097.xmlPrimary

    FORM 4